Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)

類似資料

• Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)
  著者:: Imafuku, Shinichi, 等
  出版事項: (2021)
• Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch
  著者:: Ohtsuki, Mamitaro, 等
  出版事項: (2017)
• Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results
  著者:: Umezawa, Yoshinori, 等
  出版事項: (2021)
• Long‐term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3‐year results of a double‐blind extension study
  著者:: Okubo, Yukari, 等
  出版事項: (2019)
• Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial
  著者:: Imafuku, Shinichi, 等
  出版事項: (2020)